Making Sense of Eventide Asset Management's Q3 and Q4 2022 Holdings

Eventide Asset Management, LLC recently released its SEC 13F filings for the third and fourth quarters of 2022. As a registered investment advisor, Eventide manages portfolios with a focus on creating positive social impact alongside strong financial returns. One of their funds, Eventide Gilead Fund (ETGLX), has been making headlines for its emphasis on investing in healthcare, technology, and sustainable energy companies. In this blog post, we'll take a closer look at the changes in holdings of this fund between Q3 and Q4 2022.

Overview of Eventide Gilead Fund's holdings

According to the 13F filings, Eventide Gilead Fund held a total of 73 stocks in Q3 2022, valued at around $3.6 billion. In Q4 2022, the number of holdings increased to 76, with the total value of $3.8 billion. The fund's top holdings in both quarters included MTD, DOCS, TT, ODFL, and ARGX. However, there were some significant changes in the fund's position in individual stocks, as we'll discuss in the following section.

Gain and loss leaders in Q4 2022

One of the biggest gainers in Eventide Gilead Fund's portfolio in Q4 2022 was Flywire Corporation (FLYW), with a significant increase of 138.3% in shares held. The company provides payment and receivables solutions for businesses, education, and healthcare institutions. The fund also increased its position in Horizon Therapeutics Pub L (HZNP) by 88.6%, making it the second-largest gainer in terms of holdings.

In contrast, Prometheus Biosciences Inc (RXDX) was one of the biggest losers in terms of shares held, with a decrease of 27.9%. The fund also reduced its position in The Trade Desk Inc (TTD) by 40.1%, making it the second-biggest loser in this quarter.

In terms of new positions, Eventide Gilead Fund took a stake in two companies – Royalty Pharma PLC (RPRX) and Aura Biosciences Inc (AURA). It also added Brookfield Renewable Corp (BEPC.TO) to its holdings.

The impact of the pandemic on the fund's holdings

Looking at Eventide Gilead Fund's holdings, it's clear that the impact of the COVID-19 pandemic is still evident. The fund continues to hold positions in companies that provide healthcare, technology, and sustainable energy solutions that have become more critical during the pandemic's ongoing crisis.

For instance, the fund increased its position in Doximity Inc (DOCS), an online healthcare platform that connects doctors and patients. The company's services became essential during the pandemic when more people began to seek virtual consultations with their physicians. The fund also maintained its position in Mettler Toledo International (MTD), a company that provides precision instruments for laboratory and food retailing applications, which has benefitted from an uptick in demand for rapid testing and lab equipment during the pandemic.

Conclusion

In summary, Eventide Gilead Fund's Q3 and Q4 2022 holdings reflect the company's values of investing in socially responsible and innovation-driven companies. The fund has shown a willingness to invest in companies that are making an impact in healthcare, technology, and sustainable energy, and this is evident in its portfolio.

While there were some significant changes in holdings, with some positions increased and others reduced, the fund remains true to its investment philosophy. Investors looking for opportunities to invest in companies within these sectors may find Eventide Gilead Fund an excellent way to achieve both financial and social returns.